搜索筛选:
搜索耗时3.4129秒,为你在为你在102,285,761篇论文里面共找到 28 篇相符的论文内容
发布年度:
Phase 1 studies comparing safety,tolerability,pharmacokinetics and pharmacodynamics of HLX01(a ritux
[期刊论文] 作者：Yuankai Shi,Qingyuan Zhang,Xiaohong Han,Yan Qin,Xiaoyan Ke,Hang Su,Li Liu,Jinxiang Fu,Jie Jin,Jifeng Feng,
来源：中国癌症研究（英文版） 年份：2004
Objective:This study aimed to compare the pharmacokinetic,pharmacodynamic and safety profiles of HLX01(a rituximab biosimilar)and reference rituximab sourced fr...
LUX-Lung 6: A randomized, open-label, Phase Ⅲ study of afatinib vs.gemcitabine/cisplatin as first-li
[会议论文] 作者：Yi-Long Wu,Sarayut L Geater,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Jian Hua Shi,Mei Hou,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
...
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or me
[期刊论文] 作者：Yan Song,Juxiang Xiao,Wentao Fang,Ping Lu,Qingxia Fan,Yongqian Shu,Jifeng Feng,Shu Zhang,Yi Ba,Yang Zhao,
来源：癌症生物学与医学（英文版） 年份：2021
Objective:In this post-hoc analysis, we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous c...
LUX-Lung 6: A randomized, open-label, Phase Ⅲ study of afatinib vs.gemcitabine/cisplatin as first-li
[会议论文] 作者：Yi-Long Wu,Sarayut L Geater,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Jian Hua Shi,Mei Hou,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
Background: Afatinib is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), HER2 (ErbB2) and ErbB4.Afatinib was superior to first-line pemetrexed/cisplatin in terms of pr...
A multicenter, randomized, controlled trial of S-1/Cisplatin vs.Docetaxel/Cisplatin for treatment of
[会议论文] 作者：Baohui Han,Xiaoqing Liu,Gongyan Chen,Caicun Zhou,Jiwei Liu,Hongming Pan,Cheng Huang,Shucai Zhang,Jifeng Feng,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: Platinum based doublet chemotherapy is standard treatment for treatment na(i)ve advanced NSCLC pts, although molecularly targeted therapy can improve outcome of selected patients who harbor...
[期刊论文] 作者：Yi Ba,Yuankai Shi,Wenqi Jiang,Jifeng Feng,Ying Cheng,Li Xiao,Qingyuan Zhang,Wensheng Qiu,Binghe Xu,Ruihua,
来源：癌症生物学与医学（英文版） 年份：2020
Chemotherapy-induced neutropenia (CIN) is a potentially fatal and common complication in myelosuppressive chemotherapy. The timing and grade of CIN may play pro...
[期刊论文] 作者：Wenxi Yu,Yuanjue Sun,Yang Yao,Shiying Yu,Feng Yu,Jun Ma,Jiejun Wang,Jifeng Feng,Guoping Sun,Jiliang Yin,
来源：Oncology and Translational Medicine 年份：2015
Overview Drug-induced liver injury(DILI)due to acetaminophen overdose and idiosyncratic drug reactions usually occurs 5–90 days after exposure to the causative...
An open-label, randomized, multicenter study of S-1 vs Gemcitabine in patient with advanced pancreat
[会议论文] 作者：Jianming Xu,Yan Sun,Liwei Wang,Ruihua Xu,Yi Ba,Lin Shen,Shukui Qin,Nong Xu,Li Bai,Jin Li,Chunmei Bai,Jifeng Feng,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: Gemcitabine (GEM) is a standard treatment in patients with advanced pancreatic cancer (PC).S-1 has shown a good efficacy and well safety in Japanese patients from previous studies and has b...
相关搜索：
